This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, B. K. Articles by Gutman, R. Search for Related Content PubMed PubMed Citation Articles by Chang, B. K. Articles by Gutman, R.

Inhibition of Growth of Human or Hamster Pancreatic Cancer Cell Lines by -Difluoromethylornithine Alone and Combined with cis-Diamminedichloroplatinum(II)¹

Department of Medicine, Section of Hematology/Oncology [B. K. C., R. G.], and Department of Cell and Molecular Biology [O. B.], Medical College of Georgia and Veterans Administration Medical Center, Augusta, Georgia 30910

A major problem in the therapy of pancreatic adenocarcinoma is its inherent resistance to most chemotherapeutic agents. Previously, we have reported that the four pancreatic cancer cell lines studied here have elevated levels of omithine decarboxylase, a growth-regulating enzyme, and further that the degree of elevation tends to parallel the degree of chemoresistance. On the basis of these prior findings, we investigated the effects of -difluoromethylornithine (DFMO), a specific inhibitor of omithine decarboxylase, alone and in combination with cis-diamminedi-chloroplatinum(II) (cisplatin), to which two of the four cell lines display relative resistance. The cell lines studied were: two of human origin, PANC-1 and COLO-357; and two of hamster origin, WD PaCa and PD PaCa. Colony formation (clonogenic) assays were used to evaluate drug effects. Cells were exposed continuously to DFMO in medium. For the combined treatments, cells were exposed to cisplatin for 1 hr, washed, and then plated in DFMO-containing medium. The inhibitory effects of DFMO were predominantly cytostatic, were reversible by putrescine, and were roughly additive when combined with cisplatin. Our panel of cell lines responded heterogeneously to DFMO, with PANC-1 and WD PaCa showing the most sensitivity. The combination of DFMO and cisplatin appears to be a promising experimental approach to overcoming drug resistance in pancreatic cancer.

¹ Supported by Grant CA34170, awarded by the National Cancer Institute, Department of Health and Human Services, and the Medical Research Service of the Veterans Administration. Presented in part at the annual meeting of the American Association for Cancer Research, San Diego, May 1983 (5).

² To whom requests for reprints should be addressed, at Hematology/Oncology (111E), Veterans Administration Medical Center, Augusta, GA 30910.

Received 3/ 8/84. Accepted 7/30/84.

This article has been cited by other articles:

				H. A. Hahm, V. R. Dunn, K. A. Butash, W. L. Deveraux, P. M. Woster, R. A. Casero Jr., and N. E. Davidson Combination of Standard Cytotoxic Agents with Polyamine Analogues in the Treatment of Breast Cancer Cell Lines Clin. Cancer Res., February 1, 2001; 7(2): 391 - 399. [Abstract] [Full Text]